TICKERNERD
Menu
TELATELAHealthcare · Medical Devices

TELA Stock Forecast: TELA Bio, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.97
+7.18% on the day

The 5 Wall Street analysts covering TELA Bio, Inc. hold a median 12-month price target of $2 — +106.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$43.5M
Ticker Nerd rank
31 / 100
Median analyst target
$2.00
Analysts covering
5
Revenue$19.3M−4.5% y/y
Operating income−$9.3M
Net income−$11.3M
Free cash flow−$9.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+24.2%
1M
+22.8%
YTD
−17.8%
1Y
−40.1%
From 52W high
−40.1%
From 52W low
+73.2%
$0.56
$1.62
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TELA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TELA Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
85
Size
83
Growth
60
Quality
45
Revisions
33
Value
28
Volatility
27
Momentum
25
Issuance
9

Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TELA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TELA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00$2.50$3.00Oct 25Jan 26Apr 26Jul 26TELAHigh $3.00Median $2.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $1.00Median $2.00High $3.00

The green dot is the last close — the median target sits +106.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
27 Mar 2026CitizensMaintainsMarket Outperform$5.00 → $3.00
25 Mar 2026Canaccord GenuityMaintainsBuy$4.00 → $2.00
25 Mar 2026Lake StreetMaintainsBuy$3.00 → $2.00
25 Mar 2026Piper SandlerMaintainsNeutral$1.25 → $1.00
1 Dec 2025Lake StreetMaintainsBuy—
18 Nov 2025Canaccord GenuityMaintainsBuy—
14 Nov 2025CitizensMaintainsMarket Outperform—
14 Nov 2025Piper SandlerReiteratesNeutral—
21 Mar 2025Canaccord GenuityMaintainsBuy—
21 Mar 2025Citizens Capital MarketsMaintainsMarket Outperform—
21 Mar 2025Piper SandlerDowngradeNeutral—
8 Nov 2024Piper SandlerMaintainsOverweight—
4 Oct 2024Canaccord GenuityMaintainsBuy—
13 Aug 2024Canaccord GenuityMaintainsBuy—
13 Aug 2024JMP SecuritiesMaintainsMarket Outperform—
13 Aug 2024Lake StreetMaintainsBuy—
13 Aug 2024Piper SandlerMaintainsOverweight—
25 July 2024Canaccord GenuityMaintainsBuy—
10 May 2024Piper SandlerReiteratesOverweight—
22 Mar 2024JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TELA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TELA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, TELA Bio, Inc. returned −40.1% against +17.5% for the S&P 500, dividends included.

TELA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26TELAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TELA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

TELA Bio, Inc. (TELA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 82% of US stocks

Price / sales
0.5×

Cheaper than 83% of US stocks

Price / book
−3.5×

Cheaper than 96% of US stocks

EV / EBITDA
−2.2×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
−4.5%

Higher than 20% of US stocks

Earnings growth (YoY)
−4.5%

Higher than 31% of US stocks

Gross margin
72.3%

Higher than 85% of US stocks

Operating margin
−48.1%

Higher than 17% of US stocks

Net margin
−51.5%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−615.1%

Higher than 2% of US stocks

Return on assets
−33.4%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TELA Bio, Inc. (TELA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TELA Bio, Inc. has a market value of $43.5M and an enterprise value of $71.0M.

  • Revenue in the twelve months to 30 June 2026: $79.9M. The latest quarter shrank 4.5% year on year.

  • Net income over the same four quarters: −$41.2M, a −51.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.77.

  • Free cash flow in the twelve months to 30 June 2026: −$31.6M.

  • Shares outstanding: 44.8M.

  • Trailing P/E: −1.2×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • TELA Bio, Inc. employs 218 people — $367K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

TELA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TELATELA Bio, Inc.$43.5M
31
BDMDBaird Medical Investment Holdings Ltd.$46.4M
19
QTIQT Imaging Holdings, Inc.$38.6M
23
XTNTXtant Medical Holdings, Inc.$48.5M
72
MDAISpectral AI, Inc.$49.1M
15
NSPRInspireMD, Inc.$37.0M
53
MYOMyomo, Inc.$51.5M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TELA Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TELA news & analysis

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

GlobeNewsWire · 31 Aug 2026neutral

TELA Bio announced a transition in its Chief Operating Officer and Chief Financial Officer roles alongside a strategic cost reduction initiative. As part of the efficiency program, the company plans to reduce annual operating expenses by $17.0 million, or 18%.

Why it matters — TELA watchers would care because the leadership transition and 18% operating expense reduction signal a significant operational restructuring that could affect the company's financial trajectory.

TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

TELA Bio, Inc. released its Q2 2026 earnings call transcript, published via Seeking Alpha. The transcript covers the company's second-quarter financial results and management discussion.

Why it matters — A TELA watcher would review this transcript for management commentary and financial detail on the company's Q2 2026 performance.

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 10 Aug 2026negative

TELA Bio reported a second-quarter loss of $0.20 per share, wider than the Zacks Consensus Estimate of a $0.17 loss, and lagged revenue estimates. The result compares with a $0.22 per share loss in the same period a year ago.

Why it matters — The results came in below analyst expectations for both earnings and revenue, providing an update on the company's recent financial performance for TELA watchers.

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 5 Aug 2026neutral

TELA Bio announced inducement grants under Nasdaq Rule 5635(c)(4), approving stock options to purchase 2,370,000 shares and restricted stock units covering 500,000 shares for newly-hired CEO Heather Getz (grant date August 3, 2026). The Compensation Committee also approved restricted stock units covering 95,500 shares for 11 newly-hired employees (grant date August 4, 2026), granted as an inducement material to their acceptance of employment.

Why it matters — The announcement marks the compensation structure tied to the onboarding of a new CEO and 11 new employees, signalling executive and workforce additions at TELA Bio.

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

GlobeNewsWire · 4 Aug 2026positive

TELA Bio announced that its Board of Directors has appointed Heather Getz as Chief Executive Officer and Director, effective August 4, 2026.

Why it matters — A change in CEO leadership can signal a new strategic direction for the company, and Heather Getz's appointment is a key development for investors and stakeholders tracking TELA Bio's management team.

FAQ

Frequently asked questions about TELA stock

What is the TELA stock price forecast for 2026-2027?

The 5 Wall Street analysts covering TELA Bio, Inc. have a median 12-month price target of $2, with estimates ranging from $1 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TELA stock a buy right now?

Of the 5 analysts covering TELA Bio, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TELA Bio, Inc. 31 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TELA?

As at 11 Sept 2026, TELA Bio, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).

Will TELA stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +106.2% from the last close, and Ticker Nerd's factor model ranks TELA Bio, Inc. 31 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TELA stock forecast for 2030?

No analyst covering TELA Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TELA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $3 over the next 12 months.

How has TELA stock performed over the past year?

TELA Bio, Inc. returned -40.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TELA Bio, Inc. do?

TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions for surgeons and healthcare providers.

What is the latest news on TELA?

The most recent item we track (GlobeNewsWire, 31 Aug 2026): "TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative". TELA Bio announced a transition in its Chief Operating Officer and Chief Financial Officer roles alongside a strategic cost reduction initiative. As part of the efficiency program, the company plans to reduce annual operating expenses by $17.0 million, or 18%.

Company

About TELA Bio, Inc.

TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions for surgeons and healthcare providers. The company develops and markets reinforced tissue matrix products designed for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery, with an emphasis on preserving and restoring the patient’s own anatomy. Its OviTex portfolio includes products for open, laparoscopic, and robotic procedures, as well as configurations tailored to different surgical needs in general surgery and reconstructive care. TELA Bio also supports applications that aim to reduce reliance on permanent synthetic materials while leveraging the body’s natural healing response. Headquartered in Malvern, Pennsylvania, TELA Bio serves the medical device market through products that address unmet needs in modern soft-tissue repair.

CEO Ms. Heather C. Getz C.P.A., M.B.A. · 218 employees · United States · https://www.telabio.com